ReviewClinical kidney journal2023
Obesity-related glomerulopathy in children: connecting pathophysiology to clinical care.
Review in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cardiometabolic risk in children and adolescents with obesity: a position paper of the Italian Society for Pediatric Endocrinology and Diabetology.Italian journal of pediatrics · 2024Guideline
- Severe Pediatric Diabetic Ketoacidosis Complicated by Dialysis-Requiring Acute Tubular Injury, in a Child Newly Diagnosed with Type 1 Diabetes Mellitus: A Case Report.Reports (MDPI) · 2026Article
- Multifactorial chronic kidney disease and the kidney capacity-workload balance.Nature reviews. Nephrology · 2026Review
- Association Between Intrauterine Growth Restriction and Chronic Kidney Disease: A Birth Cohort Study Analysis.Kidney medicine · 2025Article
- Systematic Review: Exosomes as Molecular Messengers in the Development of Obesity-Related Complications in Children.Current issues in molecular biology · 2025Review
- Obesity‑related kidney disease: a review on ultrasound applications.Italian journal of pediatrics · 2025Review
- Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near.Frontiers in pediatrics · 2025Review
- The global health burden of pediatric chronic kidney disease: An analysis of the Global Burden of Disease database from 1990 to 2021.PloS one · 2025Article
- The Kidney in Obesity: Current Evidence, Perspectives and Controversies.Current obesity reports · 2024Review
- Kidney Damage in Pediatric Obesity: Insights from an Emerging Perspective.Journal of clinical medicine · 2024Article
- Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axis.American journal of physiology. Cell physiology · 2024Article
- Kidney function evaluation in children and adolescents with obesity: a not-negligible need.European journal of pediatrics · 2024Review
- Parental obesity predisposes offspring to kidney dysfunction and increased susceptibility to ischemia-reperfusion injury in a sex-dependent manner.American journal of physiology. Renal physiology · 2024Article
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective.World journal of gastroenterology · 2024Article
- Not Only Metabolic Complications of Childhood Obesity.Nutrients · 2024Review
- Effects ofFrontiers in pharmacology · 2024Article
- Childhood Obesity: Insight into Kidney Involvement.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity has continued to emerge as a worldwide pandemic and has been associated with a significant increase in associated comorbidities. These include well-known conditions such as hypertension and diabetes, as well as lesser-known conditions such as obesity-related glomerulopathy (ORG). The main etiology of ORG is podocyte damage, but contributing theories include dysfunctional renin-angiotensin-aldosterone system activation, hyperinsulinemia and lipid deposition. Recent advances have made strides in understanding the complex pathophysiology of ORG. The key to treating ORG is weight loss and proteinuria reduction. Lifestyle modification, pharmacological interventions and surgery are mainstays of management. A special focus on obese children is required, as childhood obesity tracks into adulthood and primary prevention is key. In this review we discuss the pathogenesis, clinical features and established and newer treatment modalities of ORG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.